MITOMYCIN SOLN,URH
Clinical Criteria Summary
Exclusion Criteria
- Perforation of the bladder or upper urinary tract
- Contraindication or known sensitivity to mitomycin
- Glomerular Filtration Rate of <30 mL/minute
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Breastfeeding
- CBC at baseline (i.e. WBC ≥3 X109/L, ANC ≥1.5 x 109/L, Platelets ≥100,000 x 109/L, Hgb ≥9.0 mg/dL)
Inclusion Criteria
- Care is provided by a VA/VA Community Care urology or oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented
- Patients of child-bearing potential and patients with partners of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment; effective contraception used during therapy and for 6 months after the last dose (patients) or 3 months after the last dose (partners)
Additional Inclusion Criteria
- Treatment naïve, residual disease, or recurrent low-grade Upper Tract Urothelial Carcinoma: treat weekly for 6 weeks
- Monthly maintenance therapy (for 1 year) after complete response can be considered on a case-by-case basis (data on monthly maintenance therapy is not robust)